Form 4: Corcept Therapeutics Executive Sean Maduck Executes Stock Options and Sells Shares

Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics (CORT) common stock on March 18 and 19, 2024, according to a Form 4 filing with the SEC.

Summary

• Sean Maduck, President of Corcept Endocrinology, engaged in transactions involving Corcept Therapeutics (CORT) common stock.
• On March 18, 2024, Maduck exercised stock options to acquire 17,219 shares at a price of $3.88 per share and simultaneously sold the same amount of shares at $25 per share.
• Also on March 18, 2024, Maduck sold 17,219 shares.
• On March 19, 2024, Maduck exercised options to acquire 10,000 shares at $2.61 per share.
• Following these transactions, Maduck directly owns 75,222 shares of common stock and indirectly owns 10,000 shares through Duckhill Capital, LLC and 10,000 shares through Sean and Molly Maduck Living Trust.
• The sale on March 18, 2024, was executed under a pre-arranged 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: Neutral sentiment. The transactions appear to be routine option exercises and sales, with one sale executed under a pre-arranged 10b5-1 plan. There's no indication of unusual or concerning activity.

Industry Context

Insider transactions are routinely monitored as they can provide insights into management's perspective on the company's valuation and future prospects. However, exercises of options and sales under 10b5-1 plans are common and don't necessarily indicate a change in sentiment.

Comparison to Industry Standards

• Comparing Maduck's transactions to those of executives at similar-sized biotech companies like Exelixis or Incyte, the scale of these transactions appears within a normal range for option exercises and sales.
• Many executives use 10b5-1 plans to diversify their holdings and manage personal finances, which is a common practice across the pharmaceutical industry.

Key Dates